Discover how STRATA Skin Sciences' CPT code expansion aims to triple its market by 2027. Get Q3 results, growth insights, and future outlook.
Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.
We wish to point out some major issues with Abdel-Fattah and colleagues’ FUTURE study.1 Surprisingly, substantial key information is not found in the main text, but in the supplementary appendix of ...
A new procedure now available at Columbus Regional aims to give men with enlarged prostates a chance to reclaim their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback